News

Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia 19 August 2025 Cambridge UK, August 19, 2025 – Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is […]

Cambridge Cognition launches Speaker Identification Solution to Safeguard Clinical Trial Integrity 12 August 2025 Cambridge Cognition Holdings plc (AIM:COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce the commercial launch of a proprietary speaker identification solution developed to tackle duplicate participant enrolment

Trading update for period ended 30 June 2025 31st July 2025 Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announces a trading update for the six months ended 30 June 2025. Highlights ·    New Sales Orders of £6.9m (H1 2024: £3.3m) ·    Order Book of £16.4m (30

Cambridge Cognition Investment, Monument Therapeutics, Achieves Positive Phase I Results for Novel Schizophrenia Treatment 23rd June 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has achieved

Spin-out Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board Thursday 17th April Manchester, UK, 17 April 2024 – Monument Therapeutics, a precision, neuroscience company focused on the development of innovative treatments forserious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has

Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial 10 April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical

Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase

Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase

CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted 6 March 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, announces its involvement in one of the world’s largest brain health studies, the Intuition Brain Health study1, demonstrating

Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment 25 February 2025 Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used